SEC filing · 8-K

Myriad Genetics Inc: Executive or director change

Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly that includes a severance payment of $1,322,294.

Filed October 9, 2026

Neutral news

What happened

Brian Donnelly departed as Chief Commercial Officer on September 16, 2026, and his employment ended on September 21, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Myriad Genetics Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.